text: The improved survival rates for obese mice chronically treated with << vildagliptin >> suggest that chronic [[ DPP4 ]] inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.